ReP USP - Resultado da busca

Artigo de periodico
Evaluation of the nicotine metabolite ratio in smoking patients treated with varenicline and bupropion (2022)
Tomaz, Paulo Roberto Xavier; Gonçalves, Thuane Sales; Santos, Juliana Rocha; Scholz, Jaqueline; Abe, Tania Ogawa; Gaya, Patrícia Viviane; Figueiredo, Eduardo Costa; Faria, Henrique Dipe de; Martins, Isarita; Pego, Ana Miguel Fonseca; Paranhos, Beatriz Aparecida Passos Bismara ; Yonamine, Maurício ; Pereira, Alexandre Costa; Santos, Paulo Caleb Junior Lima
Source: Frontiers in Pharmacology. Unidades: FM, FCF
Subjects: METABÓLITOS, TABAGISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TOMAZ, Paulo Roberto Xavier et al. Evaluation of the nicotine metabolite ratio in smoking patients treated with varenicline and bupropion. Frontiers in Pharmacology, v. 13, p. 1-7, 2022Tradução . . Disponível em: https://doi.org/10.3389/fphar.2022.900112. Acesso em: 05 nov. 2024.
APA
Tomaz, P. R. X., Gonçalves, T. S., Santos, J. R., Scholz, J., Abe, T. O., Gaya, P. V., et al. (2022). Evaluation of the nicotine metabolite ratio in smoking patients treated with varenicline and bupropion. Frontiers in Pharmacology, 13, 1-7. doi:10.3389/fphar.2022.900112
NLM
Tomaz PRX, Gonçalves TS, Santos JR, Scholz J, Abe TO, Gaya PV, Figueiredo EC, Faria HD de, Martins I, Pego AMF, Paranhos BAPB, Yonamine M, Pereira AC, Santos PCJL. Evaluation of the nicotine metabolite ratio in smoking patients treated with varenicline and bupropion [Internet]. Frontiers in Pharmacology. 2022 ; 13 1-7.[citado 2024 nov. 05 ] Available from: https://doi.org/10.3389/fphar.2022.900112
Vancouver
Tomaz PRX, Gonçalves TS, Santos JR, Scholz J, Abe TO, Gaya PV, Figueiredo EC, Faria HD de, Martins I, Pego AMF, Paranhos BAPB, Yonamine M, Pereira AC, Santos PCJL. Evaluation of the nicotine metabolite ratio in smoking patients treated with varenicline and bupropion [Internet]. Frontiers in Pharmacology. 2022 ; 13 1-7.[citado 2024 nov. 05 ] Available from: https://doi.org/10.3389/fphar.2022.900112
Artigo de periodico
Profile of the Nicotinic Cholinergic Receptor Alpha 7 Subunit Gene Expression is Associated with Response to Varenicline Treatment (2020)
Santos, Juliana Rocha; Tomaz, Paulo Roberto Xavier; Scholz, Jaqueline Ribeiro; Gaya, Patricia Viviane; Abe, Tania Ogawa; Krieger, Jose Eduardo ; Pereira, Alexandre Costa; Santos, Paulo Caleb Junior de Lima
Source: Genes. Unidade: FM
Subjects: ENVELHECIMENTO, BIOMARCADORES, MEIA IDADE, MASCULINIDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS, Juliana Rocha et al. Profile of the Nicotinic Cholinergic Receptor Alpha 7 Subunit Gene Expression is Associated with Response to Varenicline Treatment. Genes, v. 11, n. 7, 2020Tradução . . Disponível em: https://doi.org/10.3390/genes11070746. Acesso em: 05 nov. 2024.
APA
Santos, J. R., Tomaz, P. R. X., Scholz, J. R., Gaya, P. V., Abe, T. O., Krieger, J. E., et al. (2020). Profile of the Nicotinic Cholinergic Receptor Alpha 7 Subunit Gene Expression is Associated with Response to Varenicline Treatment. Genes, 11( 7). doi:10.3390/genes11070746
NLM
Santos JR, Tomaz PRX, Scholz JR, Gaya PV, Abe TO, Krieger JE, Pereira AC, Santos PCJ de L. Profile of the Nicotinic Cholinergic Receptor Alpha 7 Subunit Gene Expression is Associated with Response to Varenicline Treatment [Internet]. Genes. 2020 ; 11( 7):[citado 2024 nov. 05 ] Available from: https://doi.org/10.3390/genes11070746
Vancouver
Santos JR, Tomaz PRX, Scholz JR, Gaya PV, Abe TO, Krieger JE, Pereira AC, Santos PCJ de L. Profile of the Nicotinic Cholinergic Receptor Alpha 7 Subunit Gene Expression is Associated with Response to Varenicline Treatment [Internet]. Genes. 2020 ; 11( 7):[citado 2024 nov. 05 ] Available from: https://doi.org/10.3390/genes11070746
Artigo de periodico
Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline (2019)
Tomaz, Paulo Roberto Xavier; Kajita, Mariana Soares; Santos, Juliana Rocha; Scholz, Jaqueline; Abe, Tania Ogawa; Gaya, Patricia Viviane; Krieger, José Eduardo ; Pereira, Alexandre Costa; Santos, Paulo Caleb Junior Lima
Source: European journal of clinical pharmacology. Unidade: FM
Subjects: POLIMORFISMO, FÁRMACOS (SISTEMA NERVOSO PERIFÉRICO), TABAGISMO, CITOCROMO P-450, GENÓTIPOS, FARMACOGENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TOMAZ, Paulo Roberto Xavier et al. Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline. European journal of clinical pharmacology, v. 75, n. 11, p. 1541-1545, 2019Tradução . . Disponível em: https://doi.org/10.1007/s00228-019-02731-z. Acesso em: 05 nov. 2024.
APA
Tomaz, P. R. X., Kajita, M. S., Santos, J. R., Scholz, J., Abe, T. O., Gaya, P. V., et al. (2019). Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline. European journal of clinical pharmacology, 75( 11), 1541-1545. doi:10.1007/s00228-019-02731-z
NLM
Tomaz PRX, Kajita MS, Santos JR, Scholz J, Abe TO, Gaya PV, Krieger JE, Pereira AC, Santos PCJL. Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline [Internet]. European journal of clinical pharmacology. 2019 ; 75( 11): 1541-1545.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1007/s00228-019-02731-z
Vancouver
Tomaz PRX, Kajita MS, Santos JR, Scholz J, Abe TO, Gaya PV, Krieger JE, Pereira AC, Santos PCJL. Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline [Internet]. European journal of clinical pharmacology. 2019 ; 75( 11): 1541-1545.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1007/s00228-019-02731-z
Artigo de periodico
CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy (2015)
Santos, Juliana Rocha; Tomaz, Paulo Roberto Xavier; Issa, Jaqueline Scholz; Abe, Tania Ogawa; Krieger, Jose Eduardo; Pereira, Alexandre Costa; Santos, Paulo C. J. L.
Source: Frontiers in Genetics. Unidade: FM
Subjects: TABAGISMO, FÁRMACOS, FUMO, POLIMORFISMO, ABANDONO DO HÁBITO DE FUMAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS, Juliana Rocha et al. CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy. Frontiers in Genetics, v. 6, p. 1-7, 2015Tradução . . Disponível em: https://doi.org/10.3389/fgene.2015.00046. Acesso em: 05 nov. 2024.
APA
Santos, J. R., Tomaz, P. R. X., Issa, J. S., Abe, T. O., Krieger, J. E., Pereira, A. C., & Santos, P. C. J. L. (2015). CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy. Frontiers in Genetics, 6, 1-7. doi:10.3389/fgene.2015.00046
NLM
Santos JR, Tomaz PRX, Issa JS, Abe TO, Krieger JE, Pereira AC, Santos PCJL. CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy [Internet]. Frontiers in Genetics. 2015 ; 6 1-7.[citado 2024 nov. 05 ] Available from: https://doi.org/10.3389/fgene.2015.00046
Vancouver
Santos JR, Tomaz PRX, Issa JS, Abe TO, Krieger JE, Pereira AC, Santos PCJL. CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy [Internet]. Frontiers in Genetics. 2015 ; 6 1-7.[citado 2024 nov. 05 ] Available from: https://doi.org/10.3389/fgene.2015.00046
Artigo de periodico
CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy (2015)
Tomaz, Paulo Roberto Xavier; Santos, Juliana Rocha; Issa, Jaqueline Scholz; Abe, Tânia Ogawa; Gaya, Patrícia Viviane; Krieger, José Eduardo; Pereira, Alexandre Costa; Santos, Paulo Caleb Júnior Lima
Source: European Journal of Clinical Pharmacology. Unidade: FM
Subjects: TABAGISMO, POLIMORFISMO, EXPRESSÃO GÊNICA, FARMACOGENÉTICA, PROMOÇÃO DA SAÚDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TOMAZ, Paulo Roberto Xavier et al. CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. European Journal of Clinical Pharmacology, v. 71, n. 9, p. 1067-1073, 2015Tradução . . Disponível em: http://link.springer.com/article/10.1007%2Fs00228-015-1896-x. Acesso em: 05 nov. 2024.
APA
Tomaz, P. R. X., Santos, J. R., Issa, J. S., Abe, T. O., Gaya, P. V., Krieger, J. E., et al. (2015). CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. European Journal of Clinical Pharmacology, 71( 9), 1067-1073. doi:10.1007/s00228-015-1896-x
NLM
Tomaz PRX, Santos JR, Issa JS, Abe TO, Gaya PV, Krieger JE, Pereira AC, Santos PCJL. CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy [Internet]. European Journal of Clinical Pharmacology. 2015 ; 71( 9): 1067-1073.[citado 2024 nov. 05 ] Available from: http://link.springer.com/article/10.1007%2Fs00228-015-1896-x
Vancouver
Tomaz PRX, Santos JR, Issa JS, Abe TO, Gaya PV, Krieger JE, Pereira AC, Santos PCJL. CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy [Internet]. European Journal of Clinical Pharmacology. 2015 ; 71( 9): 1067-1073.[citado 2024 nov. 05 ] Available from: http://link.springer.com/article/10.1007%2Fs00228-015-1896-x

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies

Indexado em